Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.1 USD +9.33% Intraday chart for Acumen Pharmaceuticals, Inc. -1.20% +6.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Acumen Pharmaceuticals Files $200 Million Mixed Shelf MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting CI
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from NASDAQ Biotechnology Index CI
Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $8 Price Target MT
Acumen Pharmaceuticals Secures $50 Million Credit Facility MT
Transcript : Acumen Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 10:00 AM
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology MT
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease CI
Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer?s During Symposium At the 16Th Annual Clinical Trials on Alzheimer?s Disease CI
Certain Stock Options of Acumen Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 17-SEP-2023. CI
Certain Common Stock of Acumen Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 17-SEP-2023. CI
UBS Adjusts Acumen Pharmaceuticals Price Target to $15 From $16, Maintains Buy Rating MT
Transcript : Acumen Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BofA Securities Reinstates Acumen Pharmaceuticals at Buy With $14 Price Target MT
Acumen Pharmaceuticals Prices Upsized $130 Million Common Stock Offering MT
Chart Acumen Pharmaceuticals, Inc.
More charts
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The Company is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.1 USD
Average target price
12.17 USD
Spread / Average Target
+196.75%
Consensus
  1. Stock
  2. Equities
  3. Stock Acumen Pharmaceuticals, Inc. - Nasdaq
  4. News Acumen Pharmaceuticals, Inc.
  5. Acumen Pharmaceuticals : Credit Suisse Starts Acumen Pharmaceuticals at Outperform with $26 PT, Notes Sole Product's High-Risk, High-Return Potential